For FY2023 Q2, ending June 30 2023, OMNICELL ($NASDAQ:OMCL) reported total revenue of USD 299.0 million; this represents a decrease of 9.8% from the same period in the previous year. Additionally, their net income decreased 62.0%, totaling USD 3.4 million.
On Tuesday, OMNICELL reported its financial earnings for the second quarter of FY2023. Unfortunately, this quarter saw a decrease in total revenue and net income compared to the same quarter last year. OMNICELL stock opened the day at $63.0 and closed at $61.7, down by 2.3% from the previous closing price of 63.2. Investors seemed to take the news as a sign of potential economic troubles for the company in the near future.
In response to the news, analysts have expressed concern over the future outlook of the company. They suggest that OMNICELL should focus on cost-cutting measures to improve their net income and increase investor confidence in the company. Though this will be a challenge, OMNICELL is confident that they are up to the task and will make the necessary adjustments in order to remain competitive in the market. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Omnicell. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Omnicell. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Omnicell. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Omnicell are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an analysis of OMNICELL‘s fundamentals and found that the company has a high health score of 8/10 according to the Star Chart. This indicates OMNICELL is well equipped to handle any crisis without the risk of bankruptcy due to its cashflows and debt. OMNICELL is strong in profitability, medium in asset, growth, and weak in dividend, thus classifying it as a ‘rhino’ type of company, which is one that has achieved moderate revenue or earnings growth. Given this, OMNICELL should be attractive to investors seeking a company with stable earnings. Investors who prioritize low-risk investments and are looking for moderate returns might be interested in OMNICELL. Additionally, OMNICELL’s moderate growth potential could be attractive to investors seeking to build long-term portfolios. As such, OMNICELL could be a good option for value-oriented investors seeking to diversify their portfolios. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products are used by hospitals, nursing homes, home health agencies, and other healthcare providers. Omnicell Inc’s competitors include Nexus AG, PrimeCare Systems Inc, 10x Genomics Inc, and other companies that provide similar products and services.
Nexus AG is a German software company that specializes in enterprise resource planning (ERP) software. The company has a market capitalization of 814.29 million euros as of 2022 and a return on equity of 11.21%. Nexus AG’s main competitors include SAP SE, Oracle Corporation, and Microsoft Corporation.
– PrimeCare Systems Inc ($OTCPK:PCYS)
PrimaCare Systems Inc is a publicly traded company with a market capitalization of $44.19 million as of March 2022. The company has a return on equity of 9.24%. PrimaCare Systems Inc is a healthcare technology company that provides software and services to healthcare providers.
10x Genomics Inc is a life sciences company that develops and sells products and services for genomic analysis. The company’s products include sequencing services, software, and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
10x Genomics has a market cap of $3.07 billion as of 2022 and a return on equity of -10.81%. The company’s products are used for genomic sequencing and analysis, and its services include software and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
For potential investors in OMNICELL, the company’s second quarter of FY2023 reported total revenue of USD 299.0 million and net income of USD 3.4 million, falling by 9.8% and 62.0% respectively from the same period in the prior year. This could be a warning sign that OMNICELL may not be on track to meet its financial goals. It is important to keep a close eye on future financial results to ensure that the company is still a viable investment.